Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
Published: 01 September 2020
13m 38sPart 5 Q&As
In this series of videos Kurt Huber, Davide Capodanno, Stefan James and Roxana Mehran discuss Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
- Review the clinical landscape for antiplatelet therapy in patients with ACS.
- Discuss recent data on DAPT for patients with ACS
- Provide expert insight on application in routine clinical practice
More from this programme
Pre-treatment in NSTE-ACS – Dead or Alive?
Choice of Antithrombotic Agent in ACS: REACT-ing to Recent Trials
Head of the 3rd Med. Dept. of Cardiology and Internal Intensive Care Medicine
Prof Kurt Huber is Head of the 3rd Med. Dept. with Cardiology and Internal Intensive Care Medicine at the Clinic Ottakring, Vienna.
Prof Huber is an interventional cardiologist with over 35 years of experience. His main research interest covers basic research (mechanisms of thrombus formation and dissolution) as well as clinical research (acute coronary syndromes, organization of STEMI networks, antithrombotic therapy in CV diseases).